Skip to main content
Clinical Trials/NCT05563142
NCT05563142
Completed
Not Applicable

Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation - the Style-AF Study

University of Luebeck3 sites in 1 country125 target enrollmentNovember 22, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
University of Luebeck
Enrollment
125
Locations
3
Primary Endpoint
Time to ambulation
Status
Completed
Last Updated
last year

Overview

Brief Summary

Prospective, randomized, controlled, multi-center study to compare the safety and efficacy of the Perclose ProStyle suture-mediated closure device (PPS) as to manual compression (MC) for venous hemostasis following single shot device (SSD) based pulmonary vein isolation (PVI).

Detailed Description

The aim of this study is to show that the time to ambulation after PVI can be reduced by deploying vascular closure device versus manual compression and a figure-of-8 suture only. Safety, efficacy and feasibility of the PPS device should be proven, too.

Registry
clinicaltrials.gov
Start Date
November 22, 2022
End Date
March 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Luebeck
Responsible Party
Principal Investigator
Principal Investigator

Prof. Roland Richard Tilz

Clinical Professor, Head of Rhythmology

University of Luebeck

Eligibility Criteria

Inclusion Criteria

  • Patients age \>18
  • Elective catheter ablation for atrial fibrillation using a 6 to 14 Fr inner diameter introducer sheath with a minimum of 1 and maximum of 2 femoral venous access sites

Exclusion Criteria

  • Active systemic or cutaneous infection, or inflammation in vicinity of the groin
  • Platelet count \< 100,000 cells/mm3
  • BMI \> 45 kg/m2 or \< 20 kg/m2
  • Attempted femoral arterial access or inadvertent arterial puncture
  • Procedural complications that interfered with routine recovery, ambulation, or discharge times
  • Incorrect sheath placement
  • Intraprocedural bleeding or thrombotic complications
  • Access site-specific eligibility criteria to exclude problems with gaining access or location of sheath

Outcomes

Primary Outcomes

Time to ambulation

Time Frame: 6 hours

elapsed time between removal of the final closure device or removal of the final sheath and when the patient can stand and walk 20 ft without evidence of venous re-bleeding from the femoral access site.

Secondary Outcomes

  • time to hemostasis(6 hours)
  • time to discharge eligibility(3 days)
  • Incidence of major adverse events(30 days)
  • total post procedure time(6 hours)
  • time to discharge(3 days)
  • Incidence of minor adverse events(30 days)
  • time to closure eligibility(6 hours)
  • Time to final hemostasis(3 days)

Study Sites (3)

Loading locations...

Similar Trials